Sign in to download full-size image Scheme 7.57. Tipranavir is a molecule active against the HIV protease enzyme. The chiral catalyst was able to rearrange a simple achiral molecule to a valuable chiral one in high enantiomeric purity that finds an application for the synthesis of tipranavir...
mainly driven by small rotary compressors, while large compressors continued to outperform. Regarding the regional split for revenue on compressors, in the Americas, the North America team performed comparatively better at down low single-digits, while Latin America was down in the mid single-...
Oxford Instruments unique new Energy Dispersive Spectrometry (EDS) IR Filter unlocks high temperature EDS analysis in the Scanning Electron Microscope (SEM). It uses a super light material to block IR radiation and provides good sensitivity for low energy X-rays (Carbon and Boron are detected) all...
mergermarket is not interested in news, by then the opportunity has usually passed. mergermarket focuses on revenue generating intelligence and proves daily that it is one of the most useful and powerful tools for the M&A market. DEAL DRIVERS – EMEA 04 foreword Welcome to the full-year 2011...
Lyon et al. “Near-Infrared Spectral Imaging for Quality Assurance of Pharma-ceutical Products: Analysis of Tablets to Assess Powder Blend Homogeneity.” AAPS PharmSciTech, 3(3) article 17, 2002, pp. 1-15. Bechard, Simon R. and Down, G.R.B.; “Infared Imaging of Pharmaceutical Materials...
camera can be set to “wake” out of standby mode and autofocus quickly enough to capture a meaningful image of motion across a field of view. This also extends the service life of the device and reduces power consumption because the device only uses full power when it detects human ...
Sunosi is the first DNRI approved to treat EDS in adults living with narcolepsy or OSA. More information about Sunosi, including Full Prescribing Information and Medication Guide, is available https://pp.jazzpharma.com/pi/sunosi.en.USPI.pdf. Closing Conditions The respective obli...
therapy (Japan) Briviact®: approval in epilepsy POS – adj. therapy (U.S.) Evenity™ (romosozumab): FRAME Phase 3 topline results Pascale Richetta joined UCB as Head of Bone Patient Value Unit Divestiture of Shannon plant (Ireland) UCB joins major pharma companies in consortium...
PharmaCyte plans to combine the Cell-in-a-Box® technology with cannabinoids to develop a unique therapy for difficult-to-treat and deadly forms of cancer, such as brain cancer. Some cannabinoids are prodrugs that must be converted into their cancer killing form. These prodrugs will be used ...